Fulphila® is an effective treatment option for patients with febrile neutropenia
For FDA approval, Fulphila® had to demonstrate that it is highly similar to an existing FDA-approved biological product referred to as the reference product or reference biologic.
In studies, Pegfilgrastim* demonstrated a 94% reduction in febrile neutropenia (FN) with patients receiving chemotherapy for up to 4 cycles
Efficacy at par with the reference product4
Confirmatory Phase III study demonstrated equivalent efficacy to the reference product4 in the reduction of chemotherapy-induced febrile neutropenia in breast cancer patients.